Author:
Yin Xin,Tang Bei,Li Jing-Huan,Wang Yan,Zhang Lan,Xie Xiao-Ying,Zhang Bo-Heng,Qiu Shuang-Jian,Wu Wei-Zhong,Ren Zheng-Gang
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996;77:2217–22.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429–42.
4. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res. 1998;4:1021–9.
5. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–8.
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献